Clinical trials
Melanoma (Skin Cancer) clinical trials
Below are recruiting melanoma (skin cancer) clinical trials, each written for real people, not researchers. We’re tracking 150 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07524114Recruiting
Blood test to find leftover cancer after treatment
This study uses a blood test to look for tiny bits of cancer DNA after you finish treatment. It may help doctors know if cancer is still there and guide next steps.
Toronto, OntarioAges 18 years+ - NCT07649681Recruiting
AI nutrition help for taste changes from cancer treatment
This study tests whether an AI-powered nutrition program can help people with taste changes caused by cancer therapy. You'll get personalized recipe suggestions and nutrition advice through an online portal to help you eat better during treatment.
Augsburg, BavariaAges 18 years+ - NCT06298734Recruiting
Exercise and diet study for melanoma patients on immunotherapy
This study tests whether adding high-intensity exercise and a high-fiber diet can improve how well immunotherapy works for people with melanoma. It might help you if you are already on immunotherapy and are not currently very active or eating a lot of fiber.
Boston, MassachusettsAges 18 years+ - NCT07440290RecruitingPhase 2/Phase 3
Dabrafenib and trametinib for BRAF V600 cancers
This trial tests two targeted drugs (dabrafenib and trametinib) for patients whose cancer has a specific change in the BRAF gene called V600. These drugs work together to block signals that help the cancer grow. The trial is for children, teenagers, and adults with many types of cancer, except for a few common ones that already have approved treatments.
BelfastAges 1 year+ - NCT07760012Recruiting
PET/CT scan for common solid tumors
This trial uses a new kind of PET/CT scan to take detailed pictures of solid tumors such as melanoma, liver, lung, breast, pancreatic, or ovarian cancer. The scan might help doctors find cancer more clearly.
Beijing, Beijing MunicipalityAges 18–75 - NCT07718243RecruitingPhase 1/Phase 2
Combining two immunotherapies for solid tumors, melanoma, and lung cancer
This trial tests a new drug (bexmarilimab) plus nivolumab (an approved immunotherapy) for people with advanced solid tumors, melanoma, or non-small cell lung cancer (NSCLC) that has stopped responding to standard treatments.
ManchesterAges 18 years+ - NCT07201376Recruiting
Testing a skin imaging device for non-melanoma skin cancer
This study tests a device that uses a special light to image skin lesions after applying an FDA-approved cream. It aims to see if the device can help doctors see benign skin growths more clearly before they are removed.
Lebanon, New HampshireAges 18 years+ - NCT07280715Recruiting
Tracking immunotherapy side effects in real time
This study uses a smartphone app to track side effects from immunotherapy (a type of cancer treatment that helps your immune system fight cancer) in people with melanoma. The goal is to better understand and manage these side effects as they happen.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT07686835RecruitingPhase 2
High-fiber diet to help immunotherapy work better in advanced melanoma
This trial tests if adding extra dietary fiber before and during immunotherapy can change gut bacteria to make the treatment more effective. It is for people with advanced melanoma who are about to start their first immunotherapy.
Nijmegen, GelderlandAges 18 years+ - NCT06910657RecruitingPhase 1
IDOV-Immune vaccine for advanced solid tumors
This trial tests an experimental virus-based treatment for people with advanced solid tumors that have stopped responding to standard therapies. The treatment is designed to infect and destroy cancer cells while boosting the immune system.
St Louis, MissouriAges 18 years+ - NCT07042243Recruiting
Florida ASCENT cancer study for patients and providers
This study looks at cancer care in Florida. If you have had cancer in the past and are not currently getting active treatment (like chemotherapy or radiation), this study may help researchers understand how to improve care.
Gainesville, FloridaAges 18–100 - NCT03452774Recruiting
AI matches your cancer tests to possible treatment trials
This trial uses an AI system to help match people with certain cancer types and specific tumor test results (like gene or protein markers) to relevant clinical trials. It may help you and your doctor find studies that fit your cancer biology faster.
Birmingham, AlabamaAges Any age - NCT03740503Recruiting
Study genes in people who respond unusually to treatment
This study looks at stored tumor samples to understand why some people respond much better or much worse than expected. The goal is to learn what the tumor’s genes might be telling doctors about response to treatment.
Toronto, OntarioAges 18 years+ - NCT04354064Recruiting
Blood DNA test to see early treatment response in solid tumors
This study looks at circulating tumor DNA, which is tiny bits of DNA found in blood, to help assess how solid tumors are responding early. It uses blood samples from healthy adults who are willing to donate.
St Louis, MissouriAges 18 years+ - NCT04498767Recruiting
Radiation to treat a few metastatic spots in rare cancers
This trial studies whether stereotactic (high-precision) radiation given in a few sessions can control rare cancers that have spread to a small number of sites. It aims to help by treating all known spots while keeping side effects manageable.
AnderlechtAges 18 years+ - NCT04844528RecruitingPhase 2
Nicotinamide for CLL patients with recent skin cancer history
This Phase 2 trial tests whether nicotinamide (a form of vitamin B3) can help people with chronic lymphocytic leukemia (CLL) who have had non-melanoma skin cancers in the past 5 years. The study looks at how well new skin cancers can be prevented or reduced.
Salt Lake City, UtahAges 18 years+ - NCT05086692RecruitingPhase 1/Phase 2
Beta-only IL-2 therapy for advanced solid tumors
This Phase 1/2 study tests a beta-only version of IL-2, an immune-stimulating treatment, to shrink or control advanced or metastatic solid tumors. It’s mainly designed to check safety and to see if it can help patients by improving tumor response.
San Diego, CaliforniaAges 18 years+ - NCT05492682RecruitingPhase 1
First-in-human treatment for cancer using a drug injected into tumors
This Phase 1 trial tests PeptiCRAd-1, a treatment injected into a tumor, to see how safe it is and whether it can shrink cancers. It studies people whose cancer has come back or can’t be treated with standard options.
FrankfurtAges 18 years+ - NCT05620290RecruitingPhase 1
MR-guided ultrasound plus radiation to help skin cancer respond
This Phase 1 study tests a new way to make radiation work better using MRI-guided focused ultrasound. It focuses on improving treatment for malignant melanoma and other skin cancers, while checking safety and how patients experience treatment.
Toronto, OntarioAges 18 years+ - NCT05779423RecruitingPhase 2
Freezing tumor plus two immunotherapies for advanced melanoma
This trial tests whether combining a local treatment that freezes a tumor (cryoablation) with two immune “checkpoint” medicines (ipilimumab and nivolumab) can better control unresectable melanoma. It may help when melanoma has grown after prior immune therapy.
Boston, MassachusettsAges 18 years+ - NCT05878964Recruiting
Study of skin health and quality of life during cancer treatment
This trial looks at how cancer treatments (anti–PD-1/PD-L1/CTLA-4 medicines or CDK inhibitors) affect your skin and overall quality of life. You may fill out questionnaires during the study to help researchers understand changes over time.
RomaAges 18 years+ - NCT05896839RecruitingPhase 1/Phase 2
Immunotherapy with prednisone and sirolimus for transplant skin cancer
This early-phase study tests whether adding immunotherapy (nivolumab and ipilimumab) to prednisone and sirolimus can control advanced skin cancers in people with kidney transplants. It aims to see how well the treatment works and how safe it is for transplant recipients.
La Jolla, CaliforniaAges 18 years+ - NCT06223659RecruitingPhase 2
EMLA cream for pain during lymphoscintigraphy for skin cancer
This trial tests whether EMLA cream can reduce pain from injections needed to map lymph nodes for certain skin cancers. If you are scheduled for lymphoscintigraphy and sentinel lymph node biopsy, you may be eligible.
Columbus, OhioAges 18–99 - NCT07341737RecruitingPhase 1/Phase 2
SL-28 for advanced solid tumors that haven’t responded to treatment
This trial tests a new drug, SL-28, for people with advanced solid tumors that haven’t responded to or cannot be treated with standard therapies. It aims to find a safe dose and see if the drug can help shrink or slow the growth of your cancer.
Adelaide, South AustraliaAges 18 years+
Hear when a new Melanoma (Skin Cancer) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Melanoma (Skin Cancer) trials by city
Studies with a site in or near these metro areas.
Melanoma (Skin Cancer) trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for melanoma (skin cancer)?
- Yes. Clin2 currently lists 150 recruiting melanoma (skin cancer) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a melanoma (skin cancer) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a melanoma (skin cancer) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.